...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
【24h】

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

机译:BCL2突变与滤泡性淋巴瘤的转化风险增加和生存期缩短有关

获取原文
获取原文并翻译 | 示例

摘要

Follicular lymphoma (FL), an indolent neoplasm caused by a t(14;18) chromosomal translocation that juxtaposes the BCL2 gene and immunoglobulin locus, has a variable clinical course and frequently undergoes transformation to an aggressive lymphoma. Although BCL2 mutations have been previously described, their relationship to FL progression remains unclear. In this study, we evaluated the frequency and nature of BCL2 mutations in 2 independent cohorts of grade 1 and 2 FLs, along with the correlation between BCL2 mutations, transformation risk, and survival. The prevalence of BCL2 coding sequence mutations was 12% in FL at diagnosis and 53% at transformation (P<.0001). The presence of these BCL2 mutations at diagnosis correlated with an increased risk of transformation (hazard ratio 3.6; 95% CI, 2.0-6.2; P<.0001) and increased risk of death due to lymphoma (median survival of 9.5 years with BCL2 mutations vs 20.4 years without; P = .012). In a multivariate analysis, BCL2 mutations and high FL international prognostic index were independent risk factors for transformation and death due to lymphoma. Some mutant Bcl-2 proteins exhibited enhanced antiapoptotic capacity in vitro. Accordingly, BCL2 mutations can affect antiapoptotic Bcl-2 function, are associated with increased activation induced cytidine deaminase expression, and correlate with increased risk of transformation and death due to lymphoma.
机译:滤泡性淋巴瘤(FL)是由t(14; 18)染色体易位引起的惰性肿瘤,与BCL2基因和免疫球蛋白基因位点并列,其临床病程可变,并经常经历转化为侵袭性淋巴瘤。尽管先前已经描述了BCL2突变,但它们与FL进展的关系仍不清楚。在这项研究中,我们评估了2个独立的1级和2级FL患者队列中BCL2突变的频率和性质,以及BCL2突变,转化风险和生存率之间的相关性。 BCL2编码序列突变的发生率在诊断时在FL中为12%,而在转化时为53%(P <.0001)。这些BCL2突变在诊断时的存在与转化风险增加(危险比3.6; 95%CI,2.0-6.2; P <.0001)和淋巴瘤导致的死亡风险增加(BCL2突变的中位生存期为9.5年)相关对比20.4年(不含P; .012)。在多变量分析中,BCL2突变和高FL国际预后指标是淋巴瘤转化和死亡的独立危险因素。一些突变的Bcl-2蛋白在体外具有增强的抗凋亡能力。因此,BCL2突变可影响抗凋亡的Bcl-2功能,与激活诱导的胞苷脱氨酶表达增加有关,并与因淋巴瘤引起的转化和死亡风险增加有关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号